Influence of commonly used pharmaceutical agents on equine bone marrow‐derived mesenchymal stem cell viability

Edmonds, R. E.; Garvican, Elaine R.; Smith, Roger K.; Dudhia, Jayesh

doi:10.1111/evj.12590

Cited by 21 publications

(18 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, Goodrich et al reported that the combination of MSCs and PRP enhance bone formation instead of cartilage in osteochondral defects created on the lateral trochlear ridge of the stifle (19). Although no practitioners reported combining corticosteroids with cell therapies, it is important to mention that adding methylprednisolone or triamcinolone to MSC cultures in vitro resulted in the rapid death of MSCs (20).…”

Section: Discussionmentioning

confidence: 99%

A Survey of Clinical Usage of Non-steroidal Intra-Articular Therapeutics by Equine Practitioners

et al. 2020

View full text Add to dashboard Cite

There are several non-steroidal intra-articular therapeutics (NSIATs) available for use by equine practitioners for the treatment of performance-limiting joint-related pathology. Information is limited on perceived clinical efficacy, recommended treatment protocols, and associated complications. Our objective with this cross-sectional survey was to investigate the current clinical usage of NSIATs by equine practitioners. An electronic cross-sectional convenience survey inquiring about the use of steroidal and NSIATS (platelet-rich plasma, autologous conditioned serum, autologous protein solution, cellular therapies, and polyacrylamide hydrogel) was distributed internationally to equine practitioners. A total of 353 surveys were completed. NSIATs were used by 87.5% of the participants. Corticosteroids and hyaluronic acid remain the intra-articular therapeutic of choice among practitioners, followed by autologous conditioned serum, platelet-rich plasma and autologous conditioned protein. Polyacrylamide hydrogel was the least used. Practitioners were more likely to use NSIATs if their caseload was > 50% equine (P < 0.001), they treated more than 10 horses intra-articularly per month (P < 0.001), and horses treated were considered English sport horses (P = 0.02). Years in practice and practice location did not influence the use of NSIATs. One of the most common reasons why NSIATs were chosen was to treat acute articular pathologies. As survey limitations, answers to questions regarding clinical response and complication rates were based on subjective estimation and practitioners recall, not clinical records. In conclusion, corticosteroids remain the most widely used intra-articular therapeutic. Among the NSIATs, blood-based products are more commonly used by practitioners, followed by cellular and synthetic products. Equine practitioners frequently use NSIATs, choosing to treat acute joint pathology more than previously reported.

show abstract

Section: Discussionmentioning

confidence: 99%

A Survey of Clinical Usage of Non-steroidal Intra-Articular Therapeutics by Equine Practitioners

et al. 2020

View full text Add to dashboard Cite

show abstract

“…After 24 h of incubation with the aforementioned treatment groups, the media and aggregates were collected separately, snap frozen in liquid nitrogen and stored at −80 • C for further analyses. The concentrations of MPA evaluated in this study were based on previous studies measuring corticosteroid-induced biosynthesis in equine chondrocytes (28,29), corticosteroid dose divided by the average estimated volume of navicular bursa/distal interphalangeal joint (8,30), and preliminary data collected in our laboratory.…”

Section: Aggregate Culturementioning

confidence: 99%

In vitro Effects of Methylprednisolone Acetate on Equine Deep Digital Flexor Tendon-Derived Cells

et al. 2020

View full text Add to dashboard Cite

Primary deep digital flexor tendon (DDFT) pathologies and those accompanying degenerative changes of navicular bone fibrocartilage are major causes of lameness associated with navicular disease. Intrasynovial corticosteroids are mainstay in the treatment due to the anti-inflammatory effects, but their effect on DDFT cell biosynthesis are unknown. The objective of this in-vitro study was to investigate the effects of methylprednisolone acetate (MPA) on cells isolated from the dorsal fibrocartilaginous region of forelimb DDFTs (DDFT-derived cells) of 5 horses (aged 11-17 years). Non-adherent aggregate cultures were established from third passage cells over a 72 to 96-h duration prior to treating with medium containing 0 (control), 0.05 and 0.5 mg/mL MPA for 24 h. Tendon and cartilage extracellular matrix (ECM) related gene expression, cell aggregate and culture medium GAG contents, culture medium collagen and MMP-3 and−13 concentrations were measured. After 24 h of treatment, only the higher MPA concentration (0.5 mg/mL) significantly down-regulated tendon ECM related genes; whereas, both MPA doses significantly down-regulated cartilage ECM related genes. MPA treatment did not affect the total GAG content of DDFT-derived cells or total GAG, soluble collagen and MMP-3 and−13 contents in culture medium compared to untreated controls. Future studies to determine the response of DDFT-derived cells with longer exposure times to corticosteroids and in the presence of inflammatory cytokines are necessary. These results are a first step in assessing the effects of intrasynovial medications on equine DDFT, for which currently no information exists.

show abstract

“…MSCs (Bohannon et al, 2013;Edmonds et al, 2016). Since the anesthetics and antibiotics form an important part of the in vivo cellular implantation, effect of these agents has to be determined for dMSCs also.…”

Section: Effect Of Available Culture Environmentmentioning

confidence: 99%

Mesenchymal stem cell basic research and applications in dog medicine

Gugjoo

Amarpal

Sharma

2019

Journal Cellular Physiology

View full text Add to dashboard Cite

The stem cells, owing to their special characteristics like self‐renewal, multiplication, homing, immunomodulation, anti‐inflammatory, and dedifferentiation are considered to carry an “all‐in‐one‐solution” for diverse clinical problems. However, the limited understanding of cellular physiology currently limits their definitive therapeutic use. Among various stem cell types, currently mesenchymal stem cells are extensively studied for dog clinical applications owing to their readily available sources, easy harvesting, and ability to differentiate both into mesodermal, as well as extramesodermal tissues. The isolated, culture expanded, and characterized cells have been applied both at preclinical as well as clinical settings in dogs with variable but mostly positive results. The results, though positive, are currently inconclusive and demands further intensive research on the properties and their dependence on the applications. Further, numerous clinical conditions of dog resemble to that of human counterparts and thus, if proved rewarding in the former may act as basis of therapy for the latter. The current review throws some light on dog mesenchymal stem cell properties and their potential therapeutic applications.

show abstract

Influence of commonly used pharmaceutical agents on equine bone marrow‐derived mesenchymal stem cell viability

Cited by 21 publications

References 33 publications

A Survey of Clinical Usage of Non-steroidal Intra-Articular Therapeutics by Equine Practitioners

A Survey of Clinical Usage of Non-steroidal Intra-Articular Therapeutics by Equine Practitioners

In vitro Effects of Methylprednisolone Acetate on Equine Deep Digital Flexor Tendon-Derived Cells

Mesenchymal stem cell basic research and applications in dog medicine

Contact Info

Product

Resources

About